Trade

with

Spectrum Pharmaceuticals Inc
(NASDAQ: SPPI)
AdChoices
7.70
-0.11
-1.41%
After Hours :
7.70
0.00
0.00%

Open

7.81

Previous Close

7.81

Volume (Avg)

491.07k (851.14k)

Day's Range

7.70-7.90

52Wk Range

6.36-10.32

Market Cap.

506.14M

Dividend Rate ( Yield )

-

Beta

1.97

Shares Outstanding

65.73M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 155.85M

    • Net Income

    • -62.13M

    • Market Cap.

    • 506.14M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -45.74

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.97

    • Forward P/E

    • -120.48

    • Price/Sales

    • 2.85

    • Price/Book Value

    • 1.91

    • Price/Cash flow

    • -16.31

      • EBITDA

      • -16.69M

      • Return on Capital %

      • -16.78

      • Return on Equity %

      • -28.71

      • Return on Assets %

      • -16.78

      • Book Value/Share

      • 4.04

      • Shares Outstanding

      • 65.73M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 15.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.07

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 41.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 40.25

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 84.23

            • 82.75

            • Pre-Tax Margin

            • -28.43

            • 39.38

            • Net Profit Margin

            • -45.74

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 80.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -17.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -19.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.35

              • 0.76

              • Current Ratio

              • 2.84

              • 2.92

              • Quick Ratio

              • 2.64

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.79

              • 2.21

              • Book Value/Share

              • 4.04

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.23

                • 217.39

                • P/E Ratio 5-Year High

                • -14.15

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.97

                • 124.82

                • Price/Sales Ratio

                • 2.85

                • 9.52

                • Price/Book Value

                • 1.91

                • 8.61

                • Price/Cash Flow Ratio

                • -16.31

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -28.71

                    (-4.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -16.78

                    (-1.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -22.71

                    (-4.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.06

                  • 1.48

                  • Asset Turnover

                  • 0.37

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -38.78M
                  Operating Margin
                  -24.89
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -16.31
                  Ownership

                  Institutional Ownership

                  67.86%

                  Top 10 Institutions

                  39.86%

                  Mutual Fund Ownership

                  38.06%

                  Float

                  84.95%

                  5% / Insider Ownership

                  4.62%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,903,900

                  • 0.00

                  • 5.94

                  • SPDR® S&P Biotech ETF

                  •  

                    1,895,574

                  • -1.92

                  • 2.77

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,211,425

                  • 25.81

                  • 1.84

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    1,169,574

                  • 0.20

                  • 1.71

                  • iShares Russell 2000 (AU)

                  •  

                    975,763

                  • -1.46

                  • 1.42

                  • Vanguard Small Cap Index

                  •  

                    973,062

                  • 0.16

                  • 1.48

                  • iShares Nasdaq Biotechnology

                  •  

                    850,418

                  • -0.47

                  • 1.24

                  • iShares US Pharmaceuticals

                  •  

                    755,405

                  • 0.00

                  • 1.10

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    655,789

                  • -1.76

                  • 1.00

                  • F&C Global Smaller Companies

                  •  

                    609,603

                  • 0.00

                  • 0.93

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Millennium Management LLC

                  •  

                    4,694,155

                  • -0.19%

                  • 7.14

                  • BlackRock Fund Advisors

                  •  

                    4,613,164

                  • +14.85%

                  • 7.02

                  • Fidelity Management and Research Company

                  •  

                    4,242,147

                  • -7.52%

                  • 6.45

                  • Vanguard Group, Inc.

                  •  

                    3,745,639

                  • +0.89%

                  • 5.70

                  • State Street Corp

                  •  

                    2,782,779

                  • -17.31%

                  • 4.23

                  • BMO Asset Management Inc.

                  •  

                    1,499,834

                  • +567.95%

                  • 2.28

                  • Dimensional Fund Advisors, Inc.

                  •  

                    1,248,240

                  • -0.48%

                  • 1.90

                  • Goldman, Sachs & Co.

                  •  

                    1,223,321

                  • -10.61%

                  • 1.86

                  • Rothschild Asset Management, Inc.

                  •  

                    1,112,790

                  • +13.95%

                  • 1.69

                  • Royal Bank Of Canada

                  •  

                    1,042,118

                  • +2.13%

                  • 1.59

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Core

                  Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., a...morend to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo...more-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.lessless

                  Key People

                  Dr. Rajesh C. Shrotriya,M.D.

                  CEO/Chairman of the Board/Director

                  Kurt A. Gustafson

                  CFO/Chief Accounting Officer/Executive VP

                  Dr. Anthony E. Maida, III

                  Director

                  Dr. Stuart M. Krassner,Sc.D.,Psy.D.

                  Director

                  Dr. Luigi Lenaz,M.D.

                  Director

                  • Spectrum Pharmaceuticals Inc

                  • 11500 South Eastern Avenue

                  • Henderson, NV 89052

                  • USA.Map

                  • Phone: +1 702 835-6300

                  • Fax: +1 702 260-7405

                  • sppirx.com

                  Incorporated

                  1987

                  Employees

                  226

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: